Sign inJoin waitlistJoin the waitlist

GK

Geoffrey Ku

Associate Attending Physician · New York Presbyterian Hospital

Credentials: · ·

History

New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2005–2007
New York Presbyterian Hospital
2002–2005
The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania
1998–2002

Research

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
JAMA Oncology · 2018 · 1,507 citations
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial
Clinical Cancer Research · 2010 · 397 citations

DI
David Ilson
58 papers
YJ
Yelena Janjigian
50 papers
LT
Laura Tang
26 papers
SM
Steven Maron
25 papers
DM
Daniela Molena
24 papers
DK
David Kelsen
22 papers
AW
Abraham Wu
21 papers
VS
Vivian Strong
21 papers
DJ
David Jones
20 papers
DC
Daniel Coit
16 papers
Manjit Bains
15 papers
SS
Smita Sihag
15 papers · 6 as a resident

Clinical trials

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Principal investigator · Recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2024–2028
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
Principal investigator · Active not recruiting · Phase 1
NRG Oncology
2021–2030
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
Principal investigator · Completed · Phase 1
Arog Pharmaceuticals, Inc.
2017–2020
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2016–2026